belongs to an innovative category, thanks to its formula combining high molecular weight hyaluronic acid (average 3MDa), chondroitin sulfate and cyclodextrin

Packaging:

• DOLATROX® hcc is a clear, sterile, non-pyrogenic and viscoelastic solution supplied in a 3 ml syringe.

Brief description:

DOLATROX® hcc is a joint fluid replacement for patients affected by degenerative or mechanical arthropathy that causes pain or limited mobility.

Hyaluronic acid is a natural polysaccharide present in many human tissues, particularly synovial fluid, and acts in joints both as a lubricant for cartilage and ligaments and as a shock absorber. According to numerous studies, hyaluronic acid injections into joints affected by osteoarthritis restore the viscosity and elasticity of the synovial fluid, resulting in reduced pain and improved joint mobility. Chondroitin sulfate is a high-molecular-weight glycosaminoglycan, one of the basic building blocks of joint cartilage. In vitro, chondroitin sulfate has demonstrated the ability to inhibit hyaluronidases, enzymes that degrade hyaluronic acid by hydrolyzing its bonds. Cyclodextrins are cyclic oligosaccharides that can improve the water solubility of certain substances by improving their stability and changing their state from liquid to viscous. Thanks to the viscosity-increasing properties of cyclodextrins, the resulting solution of hyaluronic acid and chondroitin sulfate has physical properties that guarantee better effectiveness.

HYALURONIC ACID | CHONDROITIN SULFATE | CYCLODEXTRIN:

• restores the viscosity of synovial fluid,
• reduces pain,
• improves joint mobility,
• slows down the degeneration of joint cartilage,
• inhibits the action of hyaluronidases,
• helps restore the rheological state of the joint,
• stimulates synoviocytes to produce endogenous hyaluronic acid,
• stays in the joint cavity for a long time.

EVOLUTION OF HYALURONIC ACID-BASED PRODUCTS

The latest generation combines hyaluronic acid with active ingredients designed to improve the product's effectiveness. DOLATROX® hcc belongs to this innovative category thanks to its formula combining high-molecular-weight hyaluronic acid (average 3 MDa), chondroitin sulfate, and cyclodextrin.

SYNERGY OF 3 ACTIVE INGREDIENTS:

• Hyaluronic acid (2%) - provides viscosupplementary properties that protect the joint,
• Chondroitin sulfate (2%) - has anti-inflammatory properties and provides greater resistance to hyaluronidase,
• Cyclodextrins (1%) - provide excellent rheological properties.

SURVEY TEST OF THE EFFICACY OF THE DOLATROX® hcc MEDICAL DEVICE

Key conclusions:

• 53% of patients experienced severe pain. After DOLATROX® hcc injection, the pain became mild for 63%,
• 63% of patients experienced moderate joint stiffness. 57% experienced mild stiffness following DOLATROX® hcc injection.
• The intensity of symptoms varies from moderate to mild,
• The frequency of symptoms has decreased significantly,
• 91% of doctors found DOLATROX® hcc to be effective,
• 85% of patients experienced no side effects after injection.

One pre-filled syringe of DOLATROX® hcc contains:

• Sodium salt of hyaluronic acid (2%),
• Chondroitin sulfate of marine origin (2%),
• Hydroxypropyl-betacyclodextrin (1%).

Method of administration:

*DOLATROX® hcc should be administered once per treatment; the injection can be repeated if necessary. Only a physician will assess the feasibility of a further injection based on the patient's situation. Intra-articular injection must only be administered by a qualified physician.

Medical device.

PRODUCER
Biofarma - Via Castelliere, 2 - 33036 Mereto di Tomba (UD) - Italy
Under license:
Kolinpharma Spa - Corso Europa 5, 20045 Lainate (Mi) - Italy

EXCLUSIVE DISTRIBUTOR FOR POLAND
Activlab Pharma
REGIS
Walerego Sławka Street 3a
30-633 Krakow
www.activlabpharma.pl

Due to the specific nature of the product, we suggest shipping in controlled conditions (UPS COURIER - PLN 44), any other form of shipping is chosen at the buyer's risk.

HYALURONIC ACIDS DISTRIBUTED BY ACTIVLAB PHARMA